Global Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Therapeutics Report 2016 - Pipeline Review of 3 Companies & 12 Molecules - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016" report to their offering.

Nociceptin Receptor pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by Companies and remaining by the Universities Institutes.

Nociceptin receptor also known as the nociceptin or orphanin FQ receptor or kappa-type-3 opioid receptor is a protein encoded by the OPRL1 (opioid receptor-like 1) gene. NOP receptors are located both pre- and post-synaptically in various areas of CNS. The nociceptin receptor (NOP) and its endogenous ligand, nociceptin are involved in biological functions, such as pain, anxiety, learning, and memory.

The report 'Nociceptin Receptor - Pipeline Review, H2 2016' outlays comprehensive information on the Nociceptin Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Nociceptin Receptor Overview
  3. Therapeutics Development
  4. Pipeline Products for Nociceptin Receptor - Overview
  5. Pipeline Products for Nociceptin Receptor - Comparative Analysis
  6. Nociceptin Receptor - Therapeutics under Development by Companies
  7. Nociceptin Receptor - Therapeutics under Investigation by Universities/Institutes
  8. Nociceptin Receptor Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Nociceptin Receptor - Products under Development by Companies
  13. Nociceptin Receptor - Products under Investigation by Universities/Institutes
  14. Nociceptin Receptor - Companies Involved in Therapeutics Development
  • Astraea Therapeutics, LLC
  • Grunenthal GmbH
  • Serodus ASA

For more information about this report visit http://www.researchandmarkets.com/research/36356q/nociceptin

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Addiction Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Addiction Disorders Drugs